Erythropoietin production in acute and chronic nephropathy [Elektronische Ressource] / vorgelegt von Ammar Tawosh

Abo Hasan

Description

Aus dem Institut für Pharmakologie und Toxikologie der Universität Tübingen Kommissarischer Direktor: Professor. Dr. H. Oßwald Erythropoietin production in acute and chronic obstructive nephropathy Inaugural-Dissertation zur Erlangung des Doktorgrades der Medizin der Medizinischen Fakultät der Eberhard -Karls -Universität zu Tübingen vorgelegt von Ammar Tawosh aus Aleppo/Syrien 2008 Dekan: Professor Dr. I. B. Autenrieth 1. Berichterstatter: Professor Dr. H. Oßwald 2. Berichterstatter: Professor Dr. T. Risler For my parents, Mohammad, his family, Hassan and Hasan 3 Content 1 Abbreviations................................................................................................5 2 Introduction ................................................................................................. 7 2.1 Obstructive nephropathy.............................................................

Sujets

• Gesundheit

Informations

• Publié par: eberhard_karls_universitat_tubingen
• Publié le: 01 janvier 2008
• Nombre de lectures: 16
• Langue: English
• Poids de l'ouvrage: 2 Mo

Extrait

 

 

           

Aus dem Institut für Pharmakologie und Toxikologie der Universität Tübingen Kommissarischer Direktor: Professor. Dr. H. Oßwald    

Erythropoietin production in acute and chronic obstructive nephropathy         Inaugural-Dissertation  zur Erlangung des Doktorgrades der Medizin     der Medizinischen Fakultät der Eberhard -Karls -Universität zu Tübingen       vorgelegt von     Ammar Tawosh aus   Aleppo/Syrien      2008

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

            Dekan: Professor Dr. I. B. Autenrieth

    1. Berichterstatter: Professor Dr. H. Oßwald 2. Berichterstatter: Professor Dr. T. Risler      

 

                                   

 

                                   

For my parents,   Mohammad, his family,   Hassan and Hasan  

   

 

                                                                  3                                                                                                                                                                                            nsioatvi........  1  tnet erbbA   ................................                                               Con                  ................................   2 Intro          ........udtcoi.n ................       5........................................ ................................tsurtcvi eenhporpathy........... ........................ Ob1 2. 7 ................................ ......7.........................................................................ogy.miolpide.1 E1.2  7........................... ve nephropathy..oi nnio sbrtcuit.3.1en R falctun ............ 2  8.ropaneph....thy.botso  fvi eurtcann ioatesuscad C 2.1.2   cifissal ................yh......perhpota................................  Ery   2.2 ..13.................... ..............).OPE( niteioporht ................................ otamc yr lleifni 8 .. 1.2.In4 amflna dis s liferantionltraopto, ap rtsbo     n evitcu  iisosbr      n  ....................7 .1........ et sfoE .2.2 2iSction, mPO produlc dna msilobate........e.ncraea .2.2 1. 7........ n ofatioimul3 St ..........................................................1. 7 .2ruSt1 2.ofe urct....OPE ........................................ nsioctun falicogloisyhp elpitluM2.5  5  2. ...2.................... opthsihy2.2.Pa6  .... 52.................................o  fPE.O ................................................ pro EPOion.duct ................roydphnesiro..s.rpdocuitnoa dnh  ...19  2.2.4 EPO  82 3  ............ ........hods Met ................................ ................................................................ ................................ofy ogolro pPO E.noitcud........ ................................ 26.. .3   2im Af  oseht..si........ .........29 .................... phnel ray.omctreoC 2.1.3etalartn eral ureteral li 2. 9 .3.1 1nUlita................itag( no)LUU.... ................................................................ ....92 3  ........................ ........rude..sel caocpr S.1giur ................32......  E.5.1   3ru epxsota sfor ypoxto H....ia.. ............ 13. 1.3.Me4 urasenem tfop alms aPE Oand EPO mRNA.... meshliabst-eRe3 wolf eniru fo tn....UL..er U aft................ ................................................3. 0 .3.1 ........ ....4 .3 2.3.Do2  ................................................................eped emi..ycnedn ..34.... .1 T   3.2 ................................................................otocols.ental prmirepxE 2.3  23.................................................. ..............................36 tneu foenirolf afw r teL.UU.... ........ 3   2. ..53 e-es.4 Rishmtabl ...... 2 O........................ystemic ect of sybl wop yhopix a ................ 3.2.ffE  .... 3  53..................................y.ncdeenep dse................ ................................3   3.A anylitac lprocedures...... .3  73...  OPE 1.3smla Pin......a. ................................ ................................................................

 

.37 ....

 

4

3.3.2 mRNA in renal tissue .................................................................. 38  3.4    .............................................................................Statistical methods 40   4   Results ...................................................................................................... 41   4.1   Effect of UUL duration on EPO secretion........................................... 41   4.2   Dose dependent EPO response following CO exposure.................... 42   4.3   Comparison of EPO production of the hydronephrotic kidneys following CO and low pO 2  43exposure ............................................................................   4.4    44EPO plasma levels after re-establishment of urine flow .....................   5   Discussion................................................................................................. 46   5.1    ............................................. 46Mechanisms of reduced EPO secretion   5.2   Recovery of renal EPO secretion ....................................................... 51   6   Summary................................................................................................... 52   7 References ................................................................................................ 54   8    71Acknowledgement .....................................................................................   9    72Curriculum vitae ........................................................................................                                

 

1 Abbreviations ACE angiotensin converting enzyme SAH S-adenosylhomocysteine SAHH S-adenosylhomocysteine hydrolase SAM S adenosylmethionine - ANG II angiotensin II AIDS acquired immune deficiency syndrome AT1 angiotensin II type 1 receptor AT2 angiotensin II type 2 receptor ARNT aryl hydrocarbon receptor nuclear translocator AVD arterio-venous difference BMP-7 bone morphogenetic protein-7 BS\OE blood samples\organs excision Caspases cysteine aspartate-specific proteases CFU-E colony-forming units-erythroid CO carbon Monoxide COHb carboxy hemoglobin GFR glomerular filtration rate ECM extracellular matrix EGF epidermal growth factor EPO Erythropoietin h hour Hb hemoglobin HIF hypoxia inducible factor HRE hypoxia response elements IGF-1 insulin-like growth factor-1 min minute MMP matrix metalloproteinase MP methylation potential mRNA messenger ribonucleic acid n number NFκB nuclear factorκB

5